Journal of drugs in dermatology : JDD · 2008
Photographic assessment of tretinoin microsphere gel in moderate acne.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Feldman Steven, Nighland Marge
Аннотация
BACKGROUND: True objective measures for assessing responsiveness to acne treatments are lacking. Photographic documentation can therefore be a valuable adjunct to treatment assessment.
OBJECTIVES: To photographically document the ability of tretinoin microsphere gel (TMG) 0.1% in improving facial acne.
METHODS: A standardized photographic technique was used to assess the efficacy and tolerability of TMG 0.1% applied once nightly for 12 weeks in an open-label trial involving 30 patients (Caucasian and Hispanic) ages 11 to 40 years with moderately severe facial acne.
RESULTS: An assessment of frontal, left-sided, and right-sided color photographs at week 12 indicated that TMG 0.1% reduced total, noninflammatory, and inflammatory acne lesion counts by 47.8%, 53.5%, and 33.2%, respectively; and produced an "excellent/ good" investigator's global evaluation (4-point scale) treatment response in 63.6% of patients. Tretinoin microsphere gel 0.1% was well tolerated, and more than 63% of subjects did not exhibit cutaneous adverse effects at week 12.
CONCLUSIONS: The standardized photographic technique proved to be a useful tool for documenting the efficacy of TMG 0.1% in consistently and significantly improving moderately severe facial acne over a 12-week treatment period.
OBJECTIVES: To photographically document the ability of tretinoin microsphere gel (TMG) 0.1% in improving facial acne.
METHODS: A standardized photographic technique was used to assess the efficacy and tolerability of TMG 0.1% applied once nightly for 12 weeks in an open-label trial involving 30 patients (Caucasian and Hispanic) ages 11 to 40 years with moderately severe facial acne.
RESULTS: An assessment of frontal, left-sided, and right-sided color photographs at week 12 indicated that TMG 0.1% reduced total, noninflammatory, and inflammatory acne lesion counts by 47.8%, 53.5%, and 33.2%, respectively; and produced an "excellent/ good" investigator's global evaluation (4-point scale) treatment response in 63.6% of patients. Tretinoin microsphere gel 0.1% was well tolerated, and more than 63% of subjects did not exhibit cutaneous adverse effects at week 12.
CONCLUSIONS: The standardized photographic technique proved to be a useful tool for documenting the efficacy of TMG 0.1% in consistently and significantly improving moderately severe facial acne over a 12-week treatment period.